January 4, 2019
The IMPACT Study (Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children) has reached the last patient last visit. Thank you to everyone who has contributed to reaching this important milestone!
144 participants were enrolled in the IMPACT Study (Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children), which tests whether giving increasing doses of peanut protein (oral immunotherapy) over a two-year period can induce desensitization to peanut. The trial will also address whether extended oral immunotherapy can create long-lasting tolerance to peanut. While other smaller trials have suggested that peanut immunotherapy may successfully desensitize peanut-allergic individuals, it is not known whether these effects can last without the continued consumption of peanut. The IMPACT study will help answer this question by assessing participants after they have avoided peanut for 26 weeks following completion of immunotherapy.
More Information